Invasive Compliance: A Bitter Pill to Swallow
A World Health Organization (WHO) report—"Adherence to Long-Term Therapies"—estimates that between 30 and 50% of medicines prescribed for long-term illness are not taken as...
What’s Behind AstraZeneca’s New Push for FDA Preview of DTC Ads?
Reuters reports that AstraZeneca (AZ) is "urging U.S. lawmakers to revive a program for drugmakers who want to voluntarily submit their television commercials for...
3rd Annual Pharmaceutical Market Research Summit
Leverage Pre and Post Launch Market Research Strategies to Improve Initial Product Positioning and Ongoing Strategic Decision Making
Pharma Online Ad Bellwether WebMD Foresees Ad Slowdown
"WebMD Health Corp. on Wednesday lowered its financial guidance for 2008, citing a softening ad marketplace," reported Online Media Daily (see "WebMD Dampens Financial...
7th Annual Forum on Patient Adherence, Compliance and Persistency
The pharmaceutical industry continues to face major obstacles in attaining patient persistency and compliance.
Violative Viva Viagra Video – Still There!
On April 16, 2008, the FDA's DDMAC asked Pfizer to "immediately cease dissemination of violative promotional materials for Viagra" -- namely a video on...
Networking Dinner Reception – Agenda
Join dozens of pharmaceutical marketing professionals for an evening of networking, food, and information sharing. Meet and mingle with your peers from the NortheastÂs top pharmaceutical and marketing companies. ItÂs a once-a-year opportunity.
The Real Value of Blogs for Marketing Is…
I cannot believe how much blogosphere space is being devoted to the Zyrtec "guerrilla marketing" campaign. The guerrilla aspect of that campaign is...
3rd Annual Pharmaceutical Market Research Summit
Leverage Pre and Post Launch Market Research Strategies to Improve Initial Product Positioning and Ongoing Strategic Decision Making
7th Annual Forum on Patient Adherence, Compliance and Persistency
The pharmaceutical industry continues to face major obstacles in attaining patient persistency and compliance.









